Sobi buys AstraZeneca's RSV virus drug for $1.5bn - pharmaphorum

Sobi buys AstraZeneca's RSV virus drug for $1.5bn  pharmaphorum

Sobi has completed the acquisition of AstraZeneca's Synagis (palivizumab) for $1.5 billion, plus certain conditional payments.



Comments

Popular posts from this blog

Глушители. Приборы бесшумной стрельбы